1.
Nishimoto M, Nakamae H, Koh K-R, Kosaka S, Matsumoto K, Morita K, Koh H, Nakane T, Ohsawa M, Hino M: Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. Acta Haematol 2013;130:111-114.
2.
Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grunewald K, Poewe W, Gastl G: Low concentrations of sti571 in the cerebrospinal fluid: a case report. Br J Haematol 2002;117:623-625.
3.
Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knobl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jager U, Valent P: Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007;37:808-813.
4.
Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E: CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its n-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004;83:401-402.
5.
Breccia M, Santopietro M, Cannella L, Federico V, Loglisci G, Serrao A, Petrucci L, Salaroli A, Nanni M, De Propris MS, Diverio D, Alimena G: Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. Leuk Res 2011;35:e91-e92.
6.
Bujassoum S, Rifkind J, Lipton JH: Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004;45:401-403.
7.
Isobe Y, Sugimoto K, Masuda A, Hamano Y, Oshimi K: Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Int Med J 2009;39:408-411.
8.
Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M, Tatsumi Y, Maeda Y, Kanamaru A: Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hemat 2005;81:307-309.
9.
Raanani P, Shpilberg O, Ben-Bassat I: Extramedullary disease and targeted therapies for hematological malignancies - is the association real? Ann Oncol 2007;18:7-12.
10.
Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A: Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 2004;22:179-181.
11.
Simpson E, O'Brien SG, Reilly JT: Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. Clin Lab Haematol 2006;28:215-216.
12.
Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003;304:1085-1092.
13.
Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr: The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for bcr/abl-induced leukemia. Blood 2003;101:5010-5013.
14.
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV: Mdr1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.
15.
Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012.
16.
Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Bruck P, Binckebanck A, Schleyer E, Gokbuget N, Wolff T, Lubbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9:4674-4681.
17.
Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119:106-108.
18.
Senior K: Gleevec does not cross blood-brain barrier. Lancet Oncol 2003;4:198.
19.
Radhika N, Minakshi M, Rajesh M, Manas BR, Deepak Kumar M: Central nervous system blast crisis in chronic myeloid leukemia on imatinib mesylate therapy: report of two cases. Indian J Hematol Blood Transfus 2011;27:51-54.
20.
Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM: Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 2004;10:2525-2529.
21.
Frigeri F, Arcamone M, Luciano L, Di Francia R, Pane F, Pinto A: Systemic dasatinib fails to prevent development of central nervous system progression in a patient with bcr-abl unmutated Philadelphia chromosome-positive leukemia. Blood 2009;113:5028-5029.
22.
Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521.
23.
Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590-1595.
24.
DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ: Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:5065-5071.
25.
Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T, Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT): Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707-1712.
26.
Palandri F, Amabile M, Rosti G, Bandini G, Benedetti F, Usala E, Angelucci E, Tiribelli M, Fanin R, Martinelli G, Baccarani M: Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007;39:189-191.
27.
Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, Han W, Zhang XH, Wang Y, Zhang YY, Qin YZ, Liu YR, Huang XJ: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2012;5:29.
28.
Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schafer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Bruck P, Serve H, Hoelzer D, Gokbuget N, Ottmann OG: Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 positive acute lymphoblastic leukemia. Leukemia 2012, E-pub ahead of print.
29.
Oyekunle A, Klyuchnikov E, Ocheni S, Kroger N, Zander AR, Baccarani M, Bacher U: Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011;126:30-39.
30.
Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, Radich JP: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791-2793.
31.
Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF: Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110:4614-4617.
32.
Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR, Cooperative German Transplant Study G: Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006;76:9-17.
33.
McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ: Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219-2225.
34.
Kim DW, Chung YJ, Lee S, Kim YJ, Chung NG, Kim JA, Oh IH, Kim TG, Kim YL, Goh HG, Kim SH, Cho B, Kim HJ, Min CK, Lee JW, Jin JY, Han CW, Kim JW, Min WS, Kim HK, Kim CC, Kim HJ: Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 2004;18:1907-1909.
35.
Atallah E, Kantarjian H, De Lima M, Borthakur G, Wierda W, Champlin R, Cortes J: The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood 2006;108:4520.
36.
Klyuchnikov E, Schafhausen P, Kroger N, Brummendorf TH, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuk F, Zander AR, Bacher U: Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009;122:6-10.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.